Search - tctmd.com

Displaying 81 - 100 of 420

Sort: Relevancy | Date

News Industry News

Meta-Analysis of AGGRASTAT® (Tirofiban HCl) Presented at CRT 2016 Conference

February 22, 2016

News Daily News

Cath-Lab Complications: New Analysis Pinpoints Rate and Risks of Intraprocedural Thrombotic Events in ACS

Shelley Wood

January 21, 2016

News Daily News

Complicaciones en el Laboratorio de Cateterización: Un Nuevo Análisis Define el Índice y Riesgos de los Episodios Trombóticos Intraoperatorios en el Manejo del SCA

Shelley Wood

January 21, 2016

News Daily News

PCI for Cardiogenic Shock: Mortality Has Increased, but So Has Patient Risk

Yael L. Maxwell

January 20, 2016

News Daily News

PCI para el Manejo del Shock Cardiogénico: La Mortalidad ha Aumentado Pareja al Riesgo de los Pacientes

Yael L. Maxwell

January 20, 2016

News Daily News

Symptom Duration May Be More Important Than D2B for STEMI, HORIZONS-AMI Substudy Suggests

Yael L. Maxwell

January 05, 2016

News Daily News

La Duración de los Síntomas Podría ser Más Importante que el Tiempo Puerta-Balón en el Manejo de Los Cuadros de STEMI, según un Subestudio del HORIZONS-AMI

Yael L. Maxwell

January 05, 2016

News Daily News

研究表明 PCI 进展会削弱比伐卢定在出血风险方面的优势

Todd Neale

December 14, 2015

News Daily News

Según un Análisis los Beneficios Hemorrágico de la Bivalirudina Disminuyen a medida que Avanza la PCI

Todd Neale

December 14, 2015

News Daily News

Bivalirudin’s Bleeding Benefits Dampened by PCI Advances, Analysis Shows

Todd Neale

December 14, 2015

News Conference News AHA 2015

Reversal Agents Safely Stop Effects of Novel Oral Anticoagulants

Yael L. Maxwell

November 10, 2015

News Opinion Editor's Corner TCT 2015

My Takeaways From TCT 2015

Shelley Wood

October 20, 2015

$Bivalirudin Versus Unfractionated Heparin Analysis: What Is Really Best in Which Patients?$

Presentation TCT 2015

Bivalirudin Versus Unfractionated Heparin Analysis: What Is Really Best in Which Patients?

Presenter: Carlo Briguori, Roxana Mehran, Carey D. Kimmelstiel

October 15, 2015

Presentation TCT 2015

BRAVO 3: A Prospective Randomized Trial of Bivalirudin Versus Heparin in Patients Undergoing Transcatheter Aortic Valve Replacement

Presenter: Thierry Lefevre

October 15, 2015

News Industry News

Similar Results With Bivalirudin Compared With Heparin Anticoagulation In TAVR Patients

October 15, 2015

News Conference News TCT 2015

BRAVO 3: Bivalirudin Similar to Heparin in Transfemoral TAVR

Yael L. Maxwell

October 15, 2015

News Conference News TCT 2015

Manual Thrombectomy Does Not Improve Outcomes in High-Risk STEMI Patients

October 14, 2015

News Conference News TCT 2015

Safety, Efficacy Endpoints Must Be Balanced in Clinical Trials

October 13, 2015

$Debate: Bivalirudin vs Heparin During PCI in Stable CAD? Unfractionated Heparin!$

Presentation TCT 2015

Debate: Bivalirudin vs Heparin During PCI in Stable CAD? Unfractionated Heparin!

Presenter: John A. Bittl, Robert A. Harrington, Michael S. Lee

October 12, 2015

Presentation TCT 2015

Debate: Bivalirudin vs Heparin During PCI in Stable CAD? Bivalirudin!

Presenter: John A. Bittl, Robert A. Harrington, George D. Dangas

October 12, 2015

Advertisement

Meta-Analysis of AGGRASTAT® (Tirofiban HCl) Presented at CRT 2016 Conference

Cath-Lab Complications: New Analysis Pinpoints Rate and Risks of Intraprocedural Thrombotic Events in ACS

Complicaciones en el Laboratorio de Cateterización: Un Nuevo Análisis Define el Índice y Riesgos de los Episodios Trombóticos Intraoperatorios en el Manejo del SCA

PCI for Cardiogenic Shock: Mortality Has Increased, but So Has Patient Risk

PCI para el Manejo del Shock Cardiogénico: La Mortalidad ha Aumentado Pareja al Riesgo de los Pacientes

Symptom Duration May Be More Important Than D2B for STEMI, HORIZONS-AMI Substudy Suggests

La Duración de los Síntomas Podría ser Más Importante que el Tiempo Puerta-Balón en el Manejo de Los Cuadros de STEMI, según un Subestudio del HORIZONS-AMI

研究表明 PCI 进展会削弱比伐卢定在出血风险方面的优势

Según un Análisis los Beneficios Hemorrágico de la Bivalirudina Disminuyen a medida que Avanza la PCI

Bivalirudin’s Bleeding Benefits Dampened by PCI Advances, Analysis Shows

Reversal Agents Safely Stop Effects of Novel Oral Anticoagulants

My Takeaways From TCT 2015

Bivalirudin Versus Unfractionated Heparin Analysis: What Is Really Best in Which Patients?

BRAVO 3: A Prospective Randomized Trial of Bivalirudin Versus Heparin in Patients Undergoing Transcatheter Aortic Valve Replacement

Similar Results With Bivalirudin Compared With Heparin Anticoagulation In TAVR Patients

BRAVO 3: Bivalirudin Similar to Heparin in Transfemoral TAVR

Manual Thrombectomy Does Not Improve Outcomes in High-Risk STEMI Patients

Safety, Efficacy Endpoints Must Be Balanced in Clinical Trials

Debate: Bivalirudin vs Heparin During PCI in Stable CAD? Unfractionated Heparin!

Debate: Bivalirudin vs Heparin During PCI in Stable CAD? Bivalirudin!

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content